BindingDB logo
myBDB logout
Compile Data Set for Download or QSAR

Found 2 hits Enz. Inhib. hit(s) with Target = 'Glucagon receptor' and Ligand = 'BDBM50199495'   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Glucagon receptor


(Homo sapiens (Human))
BDBM50199495
PNG
(1-(5-((2H-tetrazol-5-yl)carbamoyl)-2,3-dihydro-1H-...)
Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(C1CCc2cc(ccc12)C(=O)Nc1nnn[nH]1)C(=O)Nc1cc(Cl)cc(Cl)c1 |w:11.11,wU:7.10,wD:4.3,(23.03,-6.29,;23.04,-4.75,;24.58,-4.76,;21.5,-4.75,;23.05,-3.21,;24.38,-2.44,;24.39,-.9,;23.06,-.14,;21.72,-.9,;21.71,-2.44,;23.06,1.4,;24.4,2.17,;24.72,3.67,;26.58,3.64,;27.05,2.18,;28.38,1.42,;28.39,-.13,;27.06,-.9,;25.72,-.13,;25.73,1.41,;29.73,-.9,;29.73,-2.44,;31.06,-.12,;32.39,-.89,;32.56,-2.42,;34.06,-2.74,;34.83,-1.4,;33.8,-.26,;21.73,2.17,;21.73,3.71,;20.4,1.4,;19.06,2.17,;19.05,3.72,;17.71,4.48,;17.71,6.02,;16.39,3.71,;16.39,2.17,;15.05,1.4,;17.72,1.4,)|
Show InChI InChI=1S/C28H33Cl2N7O2/c1-28(2,3)18-6-8-22(9-7-18)37(27(39)31-21-14-19(29)13-20(30)15-21)24-11-5-16-12-17(4-10-23(16)24)25(38)32-26-33-35-36-34-26/h4,10,12-15,18,22,24H,5-9,11H2,1-3H3,(H,31,39)(H2,32,33,34,35,36,38)/t18-,22-,24?
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/a 4.90n/an/an/an/an/an/a



Merck Research Laboratories

Curated by ChEMBL


Assay Description
Displacement of [125]glucagon from human glucagon receptor expressed in CHO cells


Bioorg Med Chem Lett 17: 587-92 (2007)


Article DOI: 10.1016/j.bmcl.2006.11.014
BindingDB Entry DOI: 10.7270/Q2N58M0Q
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50199495
PNG
(1-(5-((2H-tetrazol-5-yl)carbamoyl)-2,3-dihydro-1H-...)
Show SMILES CC(C)(C)[C@H]1CC[C@@H](CC1)N(C1CCc2cc(ccc12)C(=O)Nc1nnn[nH]1)C(=O)Nc1cc(Cl)cc(Cl)c1 |w:11.11,wU:7.10,wD:4.3,(23.03,-6.29,;23.04,-4.75,;24.58,-4.76,;21.5,-4.75,;23.05,-3.21,;24.38,-2.44,;24.39,-.9,;23.06,-.14,;21.72,-.9,;21.71,-2.44,;23.06,1.4,;24.4,2.17,;24.72,3.67,;26.58,3.64,;27.05,2.18,;28.38,1.42,;28.39,-.13,;27.06,-.9,;25.72,-.13,;25.73,1.41,;29.73,-.9,;29.73,-2.44,;31.06,-.12,;32.39,-.89,;32.56,-2.42,;34.06,-2.74,;34.83,-1.4,;33.8,-.26,;21.73,2.17,;21.73,3.71,;20.4,1.4,;19.06,2.17,;19.05,3.72,;17.71,4.48,;17.71,6.02,;16.39,3.71,;16.39,2.17,;15.05,1.4,;17.72,1.4,)|
Show InChI InChI=1S/C28H33Cl2N7O2/c1-28(2,3)18-6-8-22(9-7-18)37(27(39)31-21-14-19(29)13-20(30)15-21)24-11-5-16-12-17(4-10-23(16)24)25(38)32-26-33-35-36-34-26/h4,10,12-15,18,22,24H,5-9,11H2,1-3H3,(H,31,39)(H2,32,33,34,35,36,38)/t18-,22-,24?
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/a 5.90n/an/an/an/an/an/a



Merck Research Laboratories

Curated by ChEMBL


Assay Description
Antagonist activity at human glucagon receptor transfected in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation


Bioorg Med Chem Lett 17: 587-92 (2007)


Article DOI: 10.1016/j.bmcl.2006.11.014
BindingDB Entry DOI: 10.7270/Q2N58M0Q
More data for this
Ligand-Target Pair